NASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free GYRE Stock Alerts $13.86 -1.74 (-11.15%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$13.50▼$15.7050-Day Range$13.88▼$25.0552-Week Range$3.03▼$30.40Volume125,154 shsAverage Volume82,865 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Gyre Therapeutics alerts: Email Address Gyre Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.14 out of 5 starsMedical Sector915th out of 926 stocksPharmaceutical Preparations Industry411th out of 417 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Gyre Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.30% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 50.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GYRE. Previous Next 1.7 News and Social Media Coverage News SentimentGyre Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gyre Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for GYRE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.99% of the stock of Gyre Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gyre Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gyre Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 77.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Gyre Therapeutics Stock (NASDAQ:GYRE)Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Read More GYRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GYRE Stock News HeadlinesApril 27, 2024 | finance.yahoo.comPublic companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last weekApril 13, 2024 | seekingalpha.comGyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In TimeMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 5, 2024 | investing.comGyre therapeutics director Nassim Usman sells shares worth $323,000March 26, 2024 | markets.businessinsider.comGyre Therapeutics Posts Loss In 2023March 26, 2024 | globenewswire.comGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | seekingalpha.comRNAZ TransCode Therapeutics, Inc.March 21, 2024 | globenewswire.comGyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 12, 2024 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) stock forecast and price targetFebruary 28, 2024 | seekingalpha.comTVTX Travere Therapeutics, Inc.February 22, 2024 | msn.comCantor Fitzgerald Downgrades RAPT Therapeutics (RAPT)December 21, 2023 | morningstar.comGyre Therapeutics IncDecember 15, 2023 | marketwatch.comGyre Therapeutics Names Han Ying As CEODecember 15, 2023 | finance.yahoo.comTotus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingDecember 2, 2023 | seekingalpha.comGYRENovember 16, 2023 | morningstar.comGyre Therapeutics Inc GYRENovember 13, 2023 | finance.yahoo.comGyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver MeetingNovember 10, 2023 | barrons.comGyre Therapeutics Inc.November 9, 2023 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE)See More Headlines Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/01/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CUSIPN/A CIK1124105 Webwww.catalystbiosciences.com Phone(619) 949-3681Fax336-480-2107Employees593Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.6893) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,930,000.00 Net MarginsN/A Pretax Margin-67.84% Return on EquityN/A Return on Assets-228.91% Debt Debt-to-Equity RatioN/A Current Ratio2.85 Quick Ratio2.64 Sales & Book Value Annual Sales$113.45 million Price / Sales10.44 Cash Flow$0.21 per share Price / Cash Flow66.05 Book Value$0.18 per share Price / Book77.00Miscellaneous Outstanding Shares85,420,000Free Float82,929,000Market Cap$1.18 billion OptionableNo Data Beta2.11 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Han Ying Ph.D.CEO & DirectorMr. Songjiang MaPresident & DirectorMs. Ruoyu Chen (Age 54)Interim Chief Financial Officer Mr. Weiguo YeChief Operating OfficerMs. Seline E. Miller CPA (Age 55)Senior Vice President of Finance Key CompetitorsANI PharmaceuticalsNASDAQ:ANIPMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROArcus BiosciencesNYSE:RCUSDay One BiopharmaceuticalsNASDAQ:DAWNView All Competitors GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed in 2024? Gyre Therapeutics' stock was trading at $25.69 at the beginning of the year. Since then, GYRE stock has decreased by 46.0% and is now trading at $13.86. View the best growth stocks for 2024 here. Are investors shorting Gyre Therapeutics? Gyre Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 181,900 shares, an increase of 50.1% from the March 31st total of 121,200 shares. Based on an average daily trading volume, of 78,700 shares, the short-interest ratio is currently 2.3 days. Currently, 1.3% of the shares of the company are short sold. View Gyre Therapeutics' Short Interest. When is Gyre Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GYRE earnings forecast. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GYRE) was last updated on 5/2/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
